Effectiveness of a fourth dose of covid-19 mRNA vaccine against the omicron variant among long term care residents in Ontario, Canada: test negative design study

Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2

(2022) Lihong Liu et al.   NATURE

Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants

(2022) Hung Fu Tseng et al.   NATURE MEDICINE

Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant

(2022) Nick Andrews et al.   NEW ENGLAND JOURNAL OF MEDICINE

Protection by a Fourth Dose of BNT162b2 against Omicron in Israel

(2022) Yinon M. Bar-On et al.   NEW ENGLAND JOURNAL OF MEDICINE

Fourth Dose of BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting

(2022) Ori Magen et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy of a Fourth Dose of Covid-19 mRNA Vaccine against Omicron

(2022) Gili Regev-Yochay et al.   NEW ENGLAND JOURNAL OF MEDICINE

Short term, relative effectiveness of four doses versus three doses of BNT162b2 vaccine in people aged 60 years and older in Israel: retrospective, test negative, case-control study

(2022) Sivan Gazit et al.   BMJ-British Medical Journal

Risk factors for severity of COVID-19: a rapid review to inform vaccine prioritisation in Canada

(2021) Aireen Wingert et al.   BMJ Open

Adverse Outcomes Associated With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variant B.1.351 Infection in Vaccinated Residents of a Long-Term Care Home, Ontario, Canada

(2021) Ahmed Vanker et al.   CLINICAL INFECTIOUS DISEASES

COVID-19 Outbreak Associated with a SARS-CoV-2 P.1 Lineage in a Long-Term Care Home after Implementation of a Vaccination Program – Ontario, April-May 2021

(2021) Chantal Williams et al.   CLINICAL INFECTIOUS DISEASES

Effectiveness of mRNA COVID-19 vaccines in preventing SARS-CoV-2 infections and COVID-19 hospitalisations and deaths in elderly long-term care facility residents, Spain, weeks 53 2020 to 13 2021

(2021) Clara Mazagatos et al.   Eurosurveillance

SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3

(2021) Ann R. Falsey et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effectiveness of BNT162b2 and mRNA-1273 covid-19 vaccines against symptomatic SARS-CoV-2 infection and severe covid-19 outcomes in Ontario, Canada: test negative design study

(2021) Hannah Chung et al.   BMJ-British Medical Journal

Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant — National Healthcare Safety Network, March 1–August 1, 2021

(2021) Srinivas Nanduri et al.   MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT

Interpretation of Relative Efficacy and Effectiveness for Influenza Vaccines

(2021) Nathaniel M Lewis et al.   CLINICAL INFECTIOUS DISEASES

Relative instantaneous reproduction number of Omicron SARS‐CoV‐2 variant with respect to the Delta variant in Denmark

(2021) Kimihito Ito et al.   JOURNAL OF MEDICAL VIROLOGY

Antibody Responses 3-5 Months Post-Vaccination with mRNA-1273 or BNT163b2 in Nursing Home Residents

(2021) Jessica A. Breznik et al.   Journal of the American Medical Directors Association

Nursing Home Staff Vaccination and Covid-19 Outcomes

(2021) Brian E. McGarry et al.   NEW ENGLAND JOURNAL OF MEDICINE

Excess Mortality in Long-Term Care Residents With and Without Personal Contact With Family or Friends During the COVID-19 Pandemic

(2021) Rachel D. Savage et al.   Journal of the American Medical Directors Association

Hospitalization and Mortality Rates in Long-Term Care Facilities: Does For-Profit Status Matter?

(2015) Peter Tanuseputro et al.   Journal of the American Medical Directors Association